Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group

Journal of Clinical Oncology

Volumn 25, Issue 36, 2007, Pages 5742-5747

  Hartmann, Jörg T ^a   Gauler, Thomas ^b   Metzner, Bernd ^b   Gerl, Arthur ^b   Casper, Jochen ^b   Rick, Oliver ^b   Horger, Marius ^b   Schleicher, Jan ^b   Derigs, Günter ^b   Mayer Steinacker, Regine ^b   Beyer, Jörg ^b   Kuczyk, Markus A ^b   Bokemeyer, Carsten ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED STUDY; CYTOPENIA; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; GERM CELL TUMOR; GRANULOCYTOPENIA; HUMAN; INFECTION; LEUKOCYTE COUNT; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PERIPHERAL BLOOD STEM CELL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FEASIBILITY STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IFOSFAMIDE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASMS, GERM CELL AND EMBRYONAL; PACLITAXEL; PROGNOSIS; SURVIVAL ANALYSIS; TESTICULAR NEOPLASMS;

EID: 37649025685     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.9099     Document Type: Article

References (21)

1. Birch R, Williams S, Cone A, et al: Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 4:400-407, 1986
2. International Germ Cell Cancer Collaborative Group: International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15:594-603, 1997
3. Hinton S, Catalano PJ, Einhorn LH, et al: Cisplatin, etoposide and either bleomycin or ifos-famide in the treatment of disseminated germ cell tumors: Final analysis of an intergroup trial. Cancer 97:1869-1875, 2003
4. Sonneveld DJ, Hoekstra HJ, van der Graaf WT, et al: Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer 91:1304-1315, 2001
5. Bosl GJ, Motzer RJ: Testicular germ-cell cancer. N Engl J Med 337:242-253, 1997
6. Kopp HG, Kuczyk M, Classen J, et al: Advances in the treatment of testicular cancer. Drugs 66:641-659, 2006
7. Schmoll HJ, Kollmannsberger C, Metzner B, et al: Long-term results of first-line sequential high dose VIP chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: An extended phase II study of the German Testicular Cancer Study Group. J Clin Oncol 21:4083-4091, 2003
8. Motzer RJ, Chou TC, Schwartz L, et al: Paclitaxel in germ cell cancer. Semin Oncol 22:12-15, 1995
9. Motzer RJ, Bajorin DF, Schwartz LH, et al: Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 12:2277-2283, 1994
10. Bokemeyer C, Beyer J, Metzner B, et al: Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 7:31-34, 1996
11. Hartmann JT, Nichols CR, Droz JP, et al: Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors. J Natl Cancer Inst 92:54-61, 2000
12. Hartmann JT, Fossa SD, Nichols CR, et al: Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors. J Natl Cancer Inst 93:1733-1738, 2001
13. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
14. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
15. Houldsworth J, Xiao H, Murty VV, et al: Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene 16:2345-2349, 1998
16. Kondagunta GV, Bacik J, Sheinfeld J, et al: Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol 25:85-90, 2007
17. Motzer RJ, Mazumdar M, Sheinfeld J, et al: Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 18:1173-1180, 2000
18. de Wit R, Louwerens M, de Mulder PH, et al: Management of intermediate-prognosis germ-cell cancer: Results of a phase I/II study of Taxol-BEP. Int J Cancer 83:831-833, 1999
19. Motzer RJ, Nichols CJ, Margolin KA, et al: Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 25:247-256, 2007
20. Hartmann JT, Nichols CR, Droz JP, et al: Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Ann Oncol 13:1017-1028, 2002
21. Kollmannsberger C, Nichols C, Meisner C, et al: Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: An explorative analysis using cart modeling. Ann Oncol 11:1115-1120, 2000